Anti-PD-1/IL-21 Fusion Protein Development Service

Creative Biolabs provides specialized, custom biologics engineering to create a de-risked and highly potent research candidate. We supply genetically stable fusion protein leads alongside comprehensive data packages confirming structural integrity, dual binding, and superior T-cell activation, particularly the generation of T memory cells in research models. Clients gain a validated, best-in-class molecule that overcomes the stability and toxicity challenges associated with combination cytokine delivery, accelerating their bioprogram toward advanced development stages.

Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us

Introduction of Anti-PD-1/IL-21 Fusion Protein Development Service

Targeted cytokine delivery represents the evolution of immune checkpoint blockade. The Anti-PD-1/IL-21 fusion protein leverages the PD-1 antibody to guide the potent immune stimulator IL-21 directly into the tumor microenvironment (TME). This site-specific approach enhances research potency while mitigating systemic toxicity and the immunosuppressive effects of non-targeted cytokines. Literature confirms that this strategy is superior to combination therapy and specifically drives the formation of durable memory T cells, making it a highly credible path to long-term cancer immunity research.

For an in-depth analysis of how our services can be tailored to your specific project needs, request a consultation.

Fig 1. Schematic representation of fusion protein domain assembly and IL-21 activity monitor. (OA Literature) Fig.1 Anti-PD-1 × IL-21 fusion proteins with attenuated IL-21 activity. ¹

What We Can Offer

Custom Cytokine Payload Engineering

Precision design and screening of affinity-attenuated IL-21 muteins to balance desired potency with mitigated immunogenicity risk, ensuring preclinical viability.

Durable Immunity via T_SCM Induction

Integrated, proprietary validation assays that confirm the generation and expansion of memory stem T cells (T_SCM) - the most powerful subset for long-term anti-tumor protection.

Dual Immunogenicity Risk Mitigation

Built-in preclinical risk assessment focusing on reducing both anti-drug antibody (ADA) formation and IgE-mediated hypersensitivity, de-risking your preclinical development program.

Modular Fusion Scaffold Development

Fully customized design of the heteroimmunoglobulin scaffold, enabling the rapid swap-out of targeting domains (e.g., to PD-L1, LAG-3) and personalized linker optimization to maximize stability and functionality.

How Creative Biolabs Can Help

Core steps of anti-PD-1/IL-21 fusion protein development. (Creative Biolabs Original)

Highlights

Engineered Durable Immunity

We don't just achieve tumor regression; we engineer long-term protection. Our fusion protein designs are specifically shown to drive the generation and expansion of T_SCM - the most potent, self-renewing subset of CD8⁺ T cells - which is essential for preventing relapse.

Dual Risk Mitigation Strategy

IL-21 moieties are known to be highly immunogenic. We address this upfront by using proprietary affinity-attenuated IL-21 muteins validated to reduce ADA formation and lower the risk of IgE-mediated hypersensitivity, minimizing potential issues during future in vivo studies.

Superior Efficacy over Combination Therapy

Published data demonstrates that the targeted anti-PD-1/IL-21 fusion protein is superior to administering Anti-PD-1 and soluble IL-21 separately, validating the necessity of the "Trojan Horse" delivery system for enhanced local efficacy.

Focus on the TME

Our designs specifically overcome the limitations of non-targeted delivery, ensuring high local concentration of the cytokine at the immune-suppressive tumor microenvironment while minimizing detrimental systemic activation.

To fully understand the Creative Biolabs advantage, we invite you to get a quote today.

Customer Reviews

Targeted Activation
The deployment of the Creative Biolabs' service has substantially facilitated the selective expansion of tumor-specific CD8⁺ T cell populations within our in vivo models. This precise methodology targets the PD-1⁺ exhausted T-cell cohort, thereby optimizing the therapeutic index in comparison to the administration of soluble IL-21. - J. B***s.
Mitigated Immunogenicity
The utilization of the Creative Biolabs' service has significantly improved the de-risking of our lead candidate's development potential. The incorporation of the affinity-attenuated IL-21 mutein enabled confident progression, minimizing the IgE-mediated hypersensitivity risk critical factor often overlooked in early development. - L. F***z.

FAQs

Q: Why is a fusion protein considered superior to simply combining Anti-PD-1 with soluble IL-21?

A: The fusion protein is structurally engineered for superiority because the Anti-PD-1 domain functions as a localizing anchor, concentrating the IL-21 payload specifically onto PD-1⁺ tumor-infiltrating lymphocytes (TILs). This mechanism markedly increases the local therapeutic index, minimizes systemic exposure, and has been demonstrated to be more effective than the non-linked combination in promoting durable T-cell memory within research models.

Q: What specific strategies does Creative Biolabs employ to mitigate the inherent immunogenicity risk associated with the IL-21 cytokine moiety?

A: Our established process incorporates mandatory, sensitive assays to evaluate the formation of ADA and the potential for IgE-mediated hypersensitivity early in the development pipeline, thereby ensuring the selection of the safest and most stable lead candidate.

Related Services

Next Immunocytokine Engineering Development

Design and screening of variations of the IL-21 payload or other cytokines (IL-2, IL-15) to precisely tune activity, half-life, and receptor bias for next-generation candidates.

Learn More →

ADEPT Pharmacokinetic and Pharmacodynamic Analysis

A specialized service to determine optimal dosing parameters and conduct rigorous PK/PD studies in relevant nonhuman primate models (e.g., cynomolgus monkey) to support the development transition.